Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05567029 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.
A Phase 1 study of Healthy Volunteers, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 198
- Enrollment target
- 5
- Study locations
NCT05567029 is a Phase 1 study of Healthy Volunteers that has completed, run by AbbVie. The registered enrollment target is 198 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (59% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT05567029, a Phase 1 study of Healthy Volunteers, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 198 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will assess how safe risankizumab is and how risankizumab moves through the body of adult healthy participants. Adverse Events will be assessed. Risankizumab is an investigational drug being developed for the treatment of Crohn's Disease. Participants are randomly assigned to one of the 2 treatment groups. Approximately 198 adult healthy volunteers will be enrolled in at least 4 sites across the world. All participants will receive risankizumab as subcutaneous injections in one of the 2 different formulations. There may be higher burden for participants in this trial. Participants will be confined for 10 days and followed up for 140 days. Adverse Events and blood tests will be collected.
Conditions Studied
Interventions
- DRUG Risankizumab Dose A
- DRUG Risankizumab Dose B
Study Locations (5)
California
- Anaheim Clinical Trials LLC /ID# 250098 - Anaheim
Florida
- Clinical Pharmacology of Miami /ID# 250099 - Miami
Illinois
- Acpru /Id# 249681 - Grayslake
Missouri
- Bio-Kinetic Clinical Applications, LLC /ID# 250181 - Springfield
Texas
- PPD Clinical Research Unit - Austin /ID# 250672 - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2023-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05567029
The ClinicalTrials.gov registry entry for NCT05567029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (59% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Risankizumab Dose A is the first listed.
NCT05567029 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05567029 about?
NCT05567029 is a clinical study titled "Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.". This study will assess how safe risankizumab is and how risankizumab moves through the body of adult healthy participants. Adverse Events will be assessed. Risankizumab is an investigational drug being developed for the treatment of Crohn's Disease. Participants are randomly assigned to one of the ...
What is the current status of trial NCT05567029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 198 participants. The study started on 2022-09-28. Estimated completion is 2023-04-20.
What conditions does trial NCT05567029 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT05567029?
The interventions under investigation include: Risankizumab Dose A (DRUG), Risankizumab Dose B (DRUG).
Who is sponsoring clinical trial NCT05567029?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05567029 being conducted?
This trial has 5 study locations across California, Florida, Illinois, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.